Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Linagliptin (Primary) ; CD26 antigen inhibitors; Sulfonylureas; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 28 Nov 2017 Planned End Date changed from 30 Dec 2017 to 31 May 2018.
- 28 Nov 2017 Planned primary completion date changed from 30 Dec 2017 to 31 May 2018.
- 28 Nov 2017 Status changed from recruiting to active, no longer recruiting.